By 2030, 50% or more increase in the incidence of diabetes mellitus (DM) is anticipated. Behavioral factors have been linked to the pathogenesis of type 2 DM (T2DM), including stress, anxiety, and mood swings. The overactivation of both the hypothalamic-pituitary-adrenal axis (HPA) and the sympathetic nervous system (SNS) were suggested attributes. In turn, a higher incidence of anxiety and mood swings was detected following T2DM, compared to non-diabetics, hypothetically related to the distress associated with diagnosis and management of DM. Sodium pump or Na+/K+-ATPase is a pivotal safeguard channel that maintains ionic gradients across cell membranes which expression and activity were enhanced by insulin. Functional defects of sodium pump were detected in DM as well. Recently, abnormal voltage-gated sodium channels were implicated in various neurological disorders, including anxiety and bipolar disorder. Metformin, an antidiabetic medication with a favorable therapeutic profile and pleiotropic effects, was able to enhance sodium pump activity in rodent model of T2DM. Furthermore, metformin was found to synergize with anxiolytics, added to promising outcomes in treatment-resistant bipolar depression. Hence, my brief overview will focus on metformin as a therapeutic modality addressing DM and its associated anxiety and mood swings, by affecting sodium pump.